Skip to main content
Premium Trial:

Request an Annual Quote

CST, AstraZeneca Extend Phosphorylation-based Biomarker Hunt

NEW YORK, (GenomeWeb News) - Cell Signaling Technology said today it has agreed to extend an agreement with AstraZeneca, under which the drugmaker will continue to use its technology to identify biomarkers for targeted compounds.
This is the fourth such agreement ( ) between the companies. CST said it will continue using its PhosphoScan technology to provide AstraZeneca with phosphorylation profiles of target kinases for an antibody development program that the companies are performing together under a parallel agreement.
CST Director of Business Development Christopher Bunker said the Danville, Mass.-based company will translate information it finds using the PhosphoScan into biomarker assays for AstraZeneca.
Financial terms of the agreement were not released.

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.